New Options

PROMISE I – U.S. Feasibility Study

PROMISE I is a multi-center, prospective, single-arm study conducted at seven U.S. centers encompassing end-stage — or “no option” — CLTI patients. All patients were confirmed as “No-Option” and facing imminent amputation by an independent review committee of vascular surgeons. Patients were enrolled between July 2017 and April 2019.

Patient Demographics

32 Patients

PROMISE I - Demographics | amCharts

Rutherford class 5 or 6

Ineligible for endovascular or surgical procedures to restore blood flow

12-Month Outcomes¹

N=31

PROMISE I - Primary Endpoint Amputation Free Survival | amCharts

Freedom from Amputation

Amputation-free survival

Survival

Technical success

Watch interview with PROMISE I PI Dan Clair, MD

View PROMISE I VIVA Presentation

1. Clair, Dan. “Results of the LimFlow System in the Promise I Trial” Vascular Interventional Advances Conference”. November 2019, The Wynn Las Vegas. Late Breaking Clinical Trial Presentation.

PROMISE I – U.S. Feasibility Study

Patient Demographics

32 Patients

12-Month Outcomes¹

N=31

Watch interview with PROMISE I PI Dan Clair, MD

1. Clair, Dan. “Results of the LimFlow System in the Promise I Trial” Vascular Interventional Advances Conference”. November 2019, The Wynn Las Vegas. Late Breaking Clinical Trial Presentation.

CAUTION: Investigational device. Limited by Federal law to investigational use.

©2020 LimFlow SA | Site designed by The Deciding Factor, Inc.

PROMISE I – U.S. Feasibility Study

Patient Demographics

32 Patients

12-Month Outcomes1

N=31

Watch interview with PROMISE I PI Dan Clair, MD

1. Clair, Dan. “Results of the LimFlow System in the Promise I Trial” Vascular Interventional Advances Conference”. November 2019, The Wynn Las Vegas. Late Breaking Clinical Trial Presentation.

12-Month Outcomes¹